Molecular Profiling Related to Poor Prognosis in Thyroid Carcinoma
Oncogene (2008) 27, 1554–1561 & 2008 Nature Publishing Group All rights reserved 0950-9232/08 $30.00 www.nature.com/onc ORIGINAL ARTICLE Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information C Montero-Conde1, JM Martı´ n-Campos2,3, E Lerma4, G Gimenez5, JL Martı´ nez-Guitarte6, N Combalı´ a7, D Montaner8, X Matı´ as-Guiu6, J Dopazo8,9,10, A de Leiva11,12, M Robledo1,9 and D Mauricio11,13 1Hereditary Endocrine Cancer Research Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; 2Research Institute, Santa Creu and Sant Pau Hospital, Barcelona, Spain; 3Biochemistry and Molecular Biology Department, Autonomous University of Barcelona (UAB), Barcelona, Spain; 4Pathology Service, Santa Creu and Sant Pau Hospital, Barcelona, Spain; 5Endocrinology Unit, Hospital of Sabadell, Spain; 6Department of Pathology and Molecular Genetics, Arnau de Vilanova Hospital (IRBLLEIDA), Lleida, Spain; 7Pathology Service, Hospital of Sabadell, Spain; 8Bioinformatics Department, Centro de Investigacio´n Prı´ncipe Felipe (CIPF), Valencia, Spain; 9ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Spain; 10Functional Genomics Node INB, Spain; 11Department of Endocrinology and Nutrition, Santa Creu and Sant Pau Hospital, Barcelona, Spain; 12ISCIII CIBER-BBN, Spain and 13Department of Endocrinology, Arnau de Vilanova Hospital (IRBLLEIDA), Lleida, Spain Undifferentiated and poorly differentiated thyroid tumors provide a potential prognosis predictor as well as targets are responsible for more than half of thyroid cancer for new therapies. patient deaths in spite of their low incidence. Conventional Oncogene (2008) 27, 1554–1561; doi:10.1038/sj.onc.1210792; treatments do not obtain substantial benefits, and the published online 17 September 2007 lack of alternative approaches limits patient survival.
[Show full text]